SCHEMBL6480184

SCHEMBL6480184

Cc1cc2ccccc2n1NC(=O)C1CCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ TSHR P16473 3/20 0.57
▸ HSD17B10 Q99714 3/20 0.57
▸ CYP2C19 P33261 2/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ CYP2D6 P10635 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ CASP1 P29466 1/20 0.57
▸ ALDH1A1 P00352 6/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ KDM4E B2RXH2 2/20 0.56
▸ POLB P06746 1/20 0.56
▸ THRB P10828 1/20 0.56
▸ GAA P10253 2/20 0.48
▸ MTNR1A P48039 2/20 0.46
▸ MTNR1B P49286 2/20 0.46
▸ ATM Q13315 1/20 0.45
▸ ADORA1 P30542 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480068 0.97 MEN1 (0.60) MEN1KMT2ATSHRHSD17B10CYP2C19
SCHEMBL6480930 0.96 ALDH1A1 (0.61) MEN1KMT2ATSHRHSD17B10CYP2C19
SCHEMBL6482423 0.94 TSHR (0.59) MEN1KMT2ATSHRHSD17B10CYP2C19
SCHEMBL6188501 0.76 TSHR (0.40) MEN1KMT2ATSHRHSD17B10CYP2C19
SCHEMBL31465692 0.71 MAPT (0.48) MEN1KMT2ATSHRHSD17B10CYP2C19
SCHEMBL6491958 0.71 MAOA (0.53) MEN1KMT2AHSD17B10ALDH1A1KDM4E
SCHEMBL31465676 0.70 KDM4E (0.46) MEN1KMT2ATSHRHSD17B10CYP2C19
SCHEMBL31465664 0.70 KDM4E (0.43) MEN1KMT2ATSHRHSD17B10CYP2C19
SCHEMBL31465662 0.69 KDM4E (0.43) MEN1KMT2ATSHRHSD17B10CYP2C19
SCHEMBL6488982 0.69 KMT2A (0.49) MEN1KMT2ATSHRHSD17B10CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 — — US claimed
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 MEN1 4842/4885KMT2A 3232/4885TSHR 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback